Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are experiencing starkly contrasting fortunes in the weight-loss and diabetes drug market, with Lilly’s stock surging nearly 30% since the start of 2025 while Novo has seen a decline of over 30%. This divergence is largely attributed to Lilly’s successful GLP-1 drug, tirzepatide, which has outperformed Novo’s semaglutide in weight loss efficacy, leading to significant revenue growth for Lilly—56% year-over-year in the latest quarter, compared to Novo’s projected sales decline.
The recent FDA proposal to exclude both tirzepatide and semaglutide from its 503B bulk list could further solidify Lilly’s market position by limiting competition from compounding pharmacies, which have historically siphoned off demand from these branded drugs. Following the announcement, both companies saw stock gains—Lilly up 9.8% and Novo by 4.8%—indicating investor optimism about reduced competition.
For market professionals, the key takeaway is that Eli Lilly’s dominance in the GLP-1 space appears to be strengthening, while Novo faces challenges ahead. The FDA’s potential regulatory changes could create a more favorable environment for Lilly, enhancing its revenue prospects and market share moving forward.
Source: marketbeat.com